Clinical OMICS

MAR-APR 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1093879

Contents of this Issue

Navigation

Page 39 of 51

38 Clinical OMICs March/April 2019 www.clinicalomics.com F rom its founding in 2015, Tempus set two ambitious goals: Building the world's largest library of molecular and clinical data; and an operating system to collect, sort, and analyze that data, improving its accessibility and util- ity to physicians. To that end, Tempus has launched numer- ous clinical collaborations aimed at uncovering patterns in genomic data, with the goal of helping cancer specialists predict how their patients will respond to treatment. "We don't want to create another data silo. We want to put it back into the hands of our collaborators to improve patient care," said Ryan Fukushima, Tempus COO. Over the past year, Tempus has partnered with the Amer- ican Society of Clinical Oncology to support research sites participating in ASCO's Targeted Agent and Profiling Uti- lization (TAPUR) Study, designed to describe the perfor- mance of FDA-approved, targeted drugs for advanced cancer with a potentially actionable genomic alteration. Fukushima said a critical factor in the company's success has been a willingness of stakeholders—including provid- ers, researchers, and pharma—to partner with Tempus to help make sense of its data and build better datasets for pre- cision medicine. "The second is multiple technology advancements hitting at the same time, including the prolifera- tion of cloud computing and the ability to store and compute large amounts of data at low cost, machine learning and artificial intelligence applications to clean and analyze data in ways like never before; and a million-fold reduction (2x the pace of Moore's Law) in the cost of generating genomic data due to improvements in sequencing technology," Fukushima said. Y ears before "precision medicine" became a popu- lar phrase, Geisinger launched MyCode Community Health Initiative, and in the past five years, its foresight has paid off. "Geisinger had established MyCode in 2007, anticipating the day when DNA sequencing would be cheap enough that we could begin sequencing the entire exome or genome on our patient population in order to predict and prevent inherited forms of cancer and cardiovascular disease," David Ledbetter, Ph.D., executive vice president and CSO of Geisinger, told ClinicalOMICs. MyCode has grown to attract more than 200,000 patient participants, and returned actionable results to more than 1000 participants and their families—an estimated potential impact on 5,000 total patients—who were found positive for disease-causing genomic variants in potentially life-threat- ening conditions. These include early onset cancers (breast, ovarian, colon) or early-onset heart attacks and other car- diac events. Contributing to MyCode's success, he said, has been the close and trusting relationship between Geisinger and patients in central and northeastern Pennsylvania. Patient participation through focus groups and patient-participants on MyCode's Ethics Advisory Board help ensure a very high consent/participation rate and positive impact on patient engagement systemwide, Ledbetter added. Geisinger launched the DiscovEHR partnership with Regeneron Pharmaceuti- cals in 2014 to sequence DNA of MyCode partici- pants. Regeneron created one of the world's largest DNA sequencing labs and was seeking a healthcare partner with comprehen- sive, longitudinal elec- tronic health data, with the expectation that leveraging that data with genomic data would allow identifi- cation of new drug targets. "Our interests, resources, and expertise were therefore perfectly complementary, and so a five-year collaboration was initiated, which has just been renewed for a second five-year period," Ledbetter said. David Ledbetter, EVP and CSO, Geisinger Ryan Fukushima, COO, Tempus ANNIVERSARY ISSUE

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2019